Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. (“OSIRIS” or the “Company”) (NASDAQ:OSIR) with Smith & Nephew plc.
For more information, please fill out the form below. There is no cost or obligation to you.
The firm’s investigation focuses on whether Osiris and its Board of Directors violated federal securities laws and/or breached fiduciary duties in relation to the proposed transaction with Smith & Nephew plc., including whether the solicitation material is misleading and whether the merger consideration undervalues the Company to the detriment of Osiris’s shareholders.
If you own common stock in Osiris and wish to obtain free of charge additional information about this investigation regarding your investments, please fill out the form below. You can also contact James M. Wilson, Jr., Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Osiris Therapeutics, Inc. (OSIR)
* The submission of this form does not create an attorney-client relationship.
Filed on 03/27/2019
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
James M. Wilson, Jr. firstname.lastname@example.org Phone (212) 983-9330 Fax (212) 983-9331
Nadeem Faruqi email@example.com Phone (212) 983-9330 Fax (212) 983-9331